BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38263056)

  • 21. Ox-LDL-mediated ILF3 overexpression in gastric cancer progression by activating the PI3K/AKT/mTOR signaling pathway.
    Sun D; Zhang M; Wei M; Wang Z; Qiao W; Liu P; Zhong X; Liang Y; Chen Y; Huang Y; Yu W
    Aging (Albany NY); 2022 May; 14(9):3887-3909. PubMed ID: 35507914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
    Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
    J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PDZ-binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway.
    Feng T; Jiang R; Yin L; Xu C; Ma J; Yin W; Jin J; Lu T; Liu X; Lyu Y; Yang Y; Ying L; Hu Q; Su D; Ling S
    Mol Carcinog; 2023 May; 62(5):716-726. PubMed ID: 36807309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells.
    Xu Z; Zhang Y; Jiang J; Yang Y; Shi R; Hao B; Zhang Z; Huang Z; Kim JW; Zhang G
    BMC Cancer; 2010 Apr; 10():161. PubMed ID: 20423485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytosolic acetyl-CoA synthetase affected tumor cell survival under hypoxia: the possible function in tumor acetyl-CoA/acetate metabolism.
    Yoshii Y; Furukawa T; Yoshii H; Mori T; Kiyono Y; Waki A; Kobayashi M; Tsujikawa T; Kudo T; Okazawa H; Yonekura Y; Fujibayashi Y
    Cancer Sci; 2009 May; 100(5):821-7. PubMed ID: 19445015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway.
    Li Z; Jin Q; Sun Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24406. PubMed ID: 35588431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
    Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
    Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway.
    Chen J; Chen J; Huang J; Li Z; Gong Y; Zou B; Liu X; Ding L; Li P; Zhu Z; Zhang B; Guo H; Cai C; Li J
    Aging (Albany NY); 2019 Dec; 11(23):10839-10860. PubMed ID: 31796646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PSMC4 promotes prostate carcinoma progression by regulating the CBX3-EGFR-PI3K-AKT-mTOR pathway.
    Liu K; Zhang S; Gong Y; Zhu P; Shen W; Zhang Q
    J Cell Mol Med; 2023 Aug; 27(16):2437-2447. PubMed ID: 37436074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
    Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
    Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
    J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.
    Zhang JJ; Xu WR; Chen B; Wang YY; Yang N; Wang LJ; Zhang YL
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8321-8331. PubMed ID: 31646562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor uptake of radiolabeled acetate reflects the expression of cytosolic acetyl-CoA synthetase: implications for the mechanism of acetate PET.
    Yoshii Y; Waki A; Furukawa T; Kiyono Y; Mori T; Yoshii H; Kudo T; Okazawa H; Welch MJ; Fujibayashi Y
    Nucl Med Biol; 2009 Oct; 36(7):771-7. PubMed ID: 19720289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
    Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
    Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways.
    Duan S; Huang W; Liu X; Liu X; Chen N; Xu Q; Hu Y; Song W; Zhou J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):304. PubMed ID: 30518405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.